This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes estimated from the literature were:
the rates of death, hospitalisations, and outpatient visits associated with rotavirus disease; vaccine efficacy; rates of diphtheria-tetanus toxoids-pertussis vaccine (DPT) coverage; the size of the annual birth cohort; and disability weights.
Study designs and other criteria for inclusion in the review
It appears that the primary studies have been identified selectively rather than by a systematic review of the literature. Most of the clinical data came from Asian studies or publications by the United Nations Children's Fund (UNICEF). Information on the design and other characteristics of the primary studies was not provided.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
Nineteen primary studies provided clinical data.
Methods of combining primary studies
A narrative approach appears to have been used to combine the primary estimates.
Investigation of differences between primary studies
Results of the review
The total birth cohort included 34,406,000 children in low-income countries, 27,393,000 in middle-income countries and 1,797,000 in high-income countries.
The cumulative rate of rotavirus disease-associated deaths per 1,000 live births was 3.7 in low-income countries, 1.7 in middle-income countries and 0.1 in high-income countries.
The cumulative rate of rotavirus disease-associated hospitalisations per 1,000 live births was 16.9 in low-income countries, 45.9 in middle-income countries and 41.5 in high-income countries.
The cumulative rate of rotavirus disease-associated outpatient visits per 1,000 live births was 202 in low-income countries, 218 in middle-income countries and 332 in high-income countries.
Vaccine efficacy against hospitalisations in the first year of life was 93%. Vaccine efficacy against outpatient visits was 78% in the first year of life and 75% after the first year of age.
The percentage of DPT coverage at 2 months of age (DPT-1) was 76% in low-income countries, 89% in middle-income countries and 96% in high-income countries.
The percentage of DPT coverage at 4 months of age (DPT-2) was 71% in low-income countries, 85% in middle-income countries and 96% in high-income countries.
Disability weights were not reported.
Methods used to derive estimates of effectiveness
The authors made some assumptions to derive clinical estimates that were not available from the literature.
Estimates of effectiveness and key assumptions
Vaccine efficacy against deaths and hospitalisations in the first year of life, as well as in subsequent years, was 93%. Rotavirus vaccine coverage at 2 and 4 months was the same as coverage for DPT-1 and DPT-2.
Measure of benefits used in the economic analysis
The summary benefit measures used were deaths and disability-adjusted life-years (DALYs) averted. DALYs were estimated by combining life expectancy and disability weights obtained from the literature. However, no information on the disability weights was provided. An annual discount rate of 3% was applied. The number of hospitalisations and outpatient visits was also reported.
Direct costs
The analysis of the costs was performed from the perspective of the health care system. Only the direct costs of inpatient and outpatient hospital costs associated with disease and vaccine costs were included. The hospital costs included length of stay, diagnostic tests, medications and special services. The vaccine costs included the costs of administration and expected losses from waste. The administration costs included the costs of health care personnel, training, the cold chain, storage space and educating the public. The costs associated with adverse events were not considered because vaccine trials had shown that the vaccine was safe and adverse events, if any, would have been negligible. The unit costs were not presented separately from the quantities of resources used. The resource use data were derived from published studies, while the costs came mainly from population-based weighted average of the country-specific cost estimates. Since the price of the vaccine had not been established, it was set by the authors. Discounting was not relevant as the costs were incurred during short timeframe. The price year was 2002, and all costs were inflated to 2002 values using the purchasing power parity conversion factors and official exchange rates.
The cost-effectiveness analysis was carried out for several vaccine prices. A threshold analysis was performed to estimate vaccine prices that made the vaccination programme cost-neutral. In addition, one-way sensitivity analyses were carried out to assess the robustness of the model results to variations in several inputs. In particular, the incidence of rotavirus disease-associated death, hospitalisation, outpatient visits, vaccine efficacy, vaccine administration cost and hospitalisation cost. The authors mainly set the ranges of values used.
Estimated benefits used in the economic analysis
The estimated DALYs without and with vaccination were, respectively, 4,282,751 and 1,686,962 (difference 2,595,790) in low-income countries, 1,545,417 and 417,630 (difference 1,127,787) in middle-income countries, and 6,594 and 1,107 (difference 5,487) in high-income countries.
The estimated deaths without and with vaccination were, respectively, 125,582 and 49,431 (difference 76,151) in lowincome countries, 45,198 and 12,181 (difference 33,017) in middle-income countries and 180 and 28 (difference 152) in high-income countries.
Cost results
The estimated medical costs (excluding vaccine costs) without and with vaccination were, respectively, $29, 900,179 and $12,443,207 (difference $17,456,972) in low-income countries, $114,298,215 and $31,481,684 (difference $82,816,530) in middle-income countries, and $46,885,162 and $7,854,114 (difference $39,031,048) in high-income countries. Thus, the vaccination programme avoided hospitalisation and outpatient visit costs.
However, with the inclusion of vaccine costs, the vaccination strategy was generally more expensive than the no vaccination option for all countries. The exception was for high-income countries at vaccine prices of $10 or less per course.
Synthesis of costs and benefits
Incremental cost-utility and cost-effectiveness ratios were calculated to combine the costs and benefits of the alternative screening strategies.
At vaccine prices of between $2 and $60 per course, the incremental cost per DALY averted ranged from $19 to $638 in low-income countries, from $15 to $1,364 in middle-income countries, and from cost-saving to $15,428 in highincome countries. The incremental cost per death averted ranged from $664 to $21,764 in low-income countries, from $523 to $46,575 in middle-income countries, and from cost-saving to $557,498 in high-income countries.
The "medical break-even price", namely the vaccine price at which the cost of vaccination would be exactly offset by the medical cost-savings from prevented hospitalisations and outpatient visits, was also calculated. It $0.18 per course in low-income countries, 1.46 per course in middle-income countries and $15.20 per course in high-income countries.
To meet the suggested standard of cost per DALY less than the per capita GNI, the maximum vaccine price for the 2-dose vaccine would be $43.18 per course for low-income countries, $100.50 per course for middle-income countries and $77.98 per course for high-income countries in Asia.
The sensitivity analysis showed that the variables that affected the medical cost per child were the rate of rotavirus disease-associated hospitalisations and the cost of hospitalisation more than the rate of outpatient visits. For example, a 25% change in the hospitalisation rate or the hospitalisation cost estimate led to a 15 to 21% change in the average medical cost per child. A 25% change in the rate of outpatient visits only resulted in a 4 to 10% change in the medical cost per child.
Other interesting results were as follows. If the hospitalisation rate increased by 25% in high-income countries, the cost per DALY averted would have been $7,016 instead of $8,541 at a vaccine price of $40 per course. That same 25% increase in the hospitalisation rate in low-income countries would affect the cost-utility ratio only slightly (from $105/DALY to $104/DALY). Similarly, a 50% increase in vaccine administration costs resulted in an 11% increase in the cost-utility ratio for the high-income group, but only a 2% increase in the cost-utility ratio for the low-income group.
In general, for high-income countries, the cost-utility ratios were greatly influenced by the efficacy of vaccine against hospitalisation, the rate and cost of hospitalisation, and the cost of vaccine administration. Cost-utility ratios in lowincome countries were mostly affected by estimates of mortality. Finally, for middle-income countries that may have increased treatment costs and high mortality rates, all parameters may have a substantial effect on the medical cost per child or the cost-utility ratios.
